European Journal of Clinical Pharmacology

, Volume 66, Issue 7, pp 689–696 | Cite as

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients

  • Ramasamy Kesavan
  • Sunil K. Narayan
  • Chandrasekaran Adithan
Pharmacogenetics

Abstract

Objective

Cytochrome P450 2C9 and 2C19 (CYP2C9 and CYP2C19, respectively) genetic polymorphisms play an important role in phenytoin (PHT) metabolism. We have evaluated whether these genetic polymorphisms have an effect on PHT-induced neurological toxicity in Tamilian (ethnic group native to southern India) patients with epilepsy.

Methods

We studied 292 Tamilian patients who were taking PHT for the treatment of various epileptic seizures. PHT toxicity was defined on the basis of neurological signs of toxicity and further sub-classified into mild, moderate, and severe toxicity based on clinical severity. Genomic DNA was extracted from peripheral leukocytes and genotyped for CYP2C9*2, *3 and CYP2C19*2, *3 by PCR-restriction fragment length polymorphism analysis.

Results

Of the 292 patients in the patient cohort, 58 were clinically diagnosed to have PHT toxicity. When risk ratios were calculated for each mutant CYP2C9 genotype separately, the adjusted odds ratio for CYP2C9*1/*3 was found to be 15.3 (95% confidence interval 5.8–40.3, P < 0.0001) for the cases compared to controls. When the four single nucleotide polymorphisms of CYP2C9 and CYP2C19 were analyzed using a haplotype approach, significant difference in the distribution of the C-C-G-G haplotype was observed between the cases and controls.

Conclusion

Our results show that CYP2C9 genetic polymorphisms (particularly the *3 allele) were associated with high risk of epileptic patients developing PHT-induced neurological toxicity.

Keywords

CYP2C9 CYP2C19 Epileptics Haplotypes Neurotoxicity Phenytoin 

Supplementary material

228_2010_817_MOESM1_ESM.doc (36 kb)
Supplementary Table 1CYP2C9 allele and genotype frequencies among epileptic patients without phenytoin toxicity (n = 234) and with phenytoin toxicity (n =  58). (DOC 35 kb)

References

  1. 1.
    Eadie MJ (1987) Neurological diseases. In: Sepight (ed) Avery’s drug treatment. Principles and practices of clinical pharmacology and therapeutics. Adis, Auckland, pp 01–64Google Scholar
  2. 2.
    Seger D (1990) Phenytoin and other anticonvulsants. In: Haddad LM, Winchester JF (eds) Clinical management of poisoning and drug overdose. WB Saunders, New York, pp 877–893Google Scholar
  3. 3.
    Aynacioglu AS, Brockmoller J, Bauer S, Sachse C, Guzelbey P, Ongen Z, Nacak M, Roots I (1999) Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 48:409–415CrossRefPubMedGoogle Scholar
  4. 4.
    Hashimoto Y, Otsuki Y, Odani A, Takano M, Hattori H, Furusho K, Lui K (1996) Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Biol Pharm Bull 19:1103–1105PubMedGoogle Scholar
  5. 5.
    Kerb R, Aynacioglu AS, Brockmoller J, Schlagenhaufer R, Bauer S, Szekeres T, Hamwi A, Fritzer-Szekeres M, Baumgartner C, Ongen HZ, Guzelbey P, Roots I, Brinkmann U (2001) The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 1:204–210PubMedGoogle Scholar
  6. 6.
    Mamiya K, Ieiri I, Shimamoto J, Yukawa E, Imai J, Ninomiya H, Yamada H, Otsubo K, Higuchi S, Tashiro N (1998) The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 39:1317–1323CrossRefPubMedGoogle Scholar
  7. 7.
    Odani A, Hashimoto Y, Otsuki Y, Uwai Y, Hattori H, Furusho K, Inui K (1997) Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther 62:287–292CrossRefPubMedGoogle Scholar
  8. 8.
    Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K (2000) CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 10:95–104CrossRefPubMedGoogle Scholar
  9. 9.
    Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR (1994) Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4:39–42CrossRefPubMedGoogle Scholar
  10. 10.
    Rettie AE, Haining RL, Bajpai M, Levy RH (1999) A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res 35:253–255CrossRefPubMedGoogle Scholar
  11. 11.
    de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419–15422PubMedGoogle Scholar
  12. 12.
    de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594–598PubMedGoogle Scholar
  13. 13.
    Bae JW, Kim HK, Kim JH, Yang SI, Kim MJ, Jang CG, Park YS, Lee SY (2005) Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol 60:418–422CrossRefPubMedGoogle Scholar
  14. 14.
    Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S (1998) Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit 20:243–247CrossRefPubMedGoogle Scholar
  15. 15.
    Lea RA, Roberts RL, Green MR, Kennedy MA, Chambers GK (2008) Allele frequency differences of cytochrome P450 polymorphisms in a sample of New Zealand Maori. N Z Med J 121:33–37PubMedGoogle Scholar
  16. 16.
    Peyvandi F, Spreafico M, Karimi M, Zeinali S, Mannucci PM, Bianchi BA (2002) Allele frequency of CYP2C9 gene polymorphisms in Iran. Thromb Haemost 88:874–875PubMedGoogle Scholar
  17. 17.
    Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M (2001) Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 52:447–450CrossRefPubMedGoogle Scholar
  18. 18.
    Scordo MG, Caputi AP, D’Arrigo C, Fava G, Spina E (2004) Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 50:195–200CrossRefPubMedGoogle Scholar
  19. 19.
    Xie HG, Prasad HC, Kim RB, Stein CM (2002) CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 54:1257–1270CrossRefPubMedGoogle Scholar
  20. 20.
    Yang JQ, Morin S, Verstuyft C, Fan LA, Zhang Y, Xu CD, Barbu V, Funck-Brentano C, Jaillon P, Becquemont L (2003) Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam Clin Pharmacol 17:373–376CrossRefPubMedGoogle Scholar
  21. 21.
    Yukawa E, Mamiya K (2006) Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using non-linear mixed effects model approach. J Clin Pharm Ther 31:275–282CrossRefPubMedGoogle Scholar
  22. 22.
    Watanabe M, Iwahashi K, Kugoh T, Suwaki H (1998) The relationship between phenytoin pharmacokinetics and the CYP2C19 genotype in Japanese epileptic patients. Clin Neuropharmacol 21:122–126PubMedGoogle Scholar
  23. 23.
    Bajpai M, Roskos LK, Shen DD, Levy RH (1996) Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 24:1401–1403PubMedGoogle Scholar
  24. 24.
    Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA (2001) Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 11:803–808CrossRefPubMedGoogle Scholar
  25. 25.
    Lee AY, Kim MJ, Chey WY, Choi J, Kim BG (2004) Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions. Eur J Clin Pharmacol 60:155–159CrossRefPubMedGoogle Scholar
  26. 26.
    Ninomiya H, Mamiya K, Matsuo S, Ieiri I, Higuchi S, Tashiro N (2000) Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. Ther Drug Monit 22:230–232CrossRefPubMedGoogle Scholar
  27. 27.
    Hennessy S, Leonard CE, Freeman CP, Metlay JP, Chu X, Strom BL, Bilker WB (2009) CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity. J Clin Pharmacol 49:1483–1487CrossRefPubMedGoogle Scholar
  28. 28.
    Citerio G, Nobili A, Airoldi L, Pastorelli R, Patruno A (2003) Severe intoxication after phenytoin infusion: a preventable pharmacogenetic adverse reaction. Neurology 60:1395–1396PubMedGoogle Scholar
  29. 29.
    McCluggage LK, Voils SA, Bullock MR (2009) Phenytoin toxicity due to genetic polymorphism. Neurocrit Care 10:222–224CrossRefPubMedGoogle Scholar
  30. 30.
    Reich D, Thangaraj K, Patterson N, Price AL, Singh L (2009) Reconstructing Indian population history. Nature 461:489–494CrossRefPubMedGoogle Scholar
  31. 31.
    Adithan C, Gerard N, Vasu S, Balakrishnan R, Shashindran CH, Krishnamoorthy R (2003) Allele and genotype frequency of CYP2C9 in Tamilnadu population. Eur J Clin Pharmacol 59:707–709CrossRefPubMedGoogle Scholar
  32. 32.
    Jose R, Chandrasekaran A, Sam SS, Gerard N, Chanolean S, Abraham BK, Satyanarayanamoorthy K, Peter A, Rajagopal K (2005) CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. Fundam Clin Pharmacol 19:101–105CrossRefPubMedGoogle Scholar
  33. 33.
    Adithan C, Gerard N, Vasu S, Rosemary J, Shashindran CH, Krishnamoorthy R (2003) Allele and genotype frequency of CYP2C19 in a Tamilian population. Br J Clin Pharmacol 56:331–333CrossRefPubMedGoogle Scholar
  34. 34.
    Rosemary J, Surendiran A, Rajan S, Shashindran CH, Adithan C (2006) Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India. Indian J Med Res 123:665–670PubMedGoogle Scholar
  35. 35.
    Jose L, Binila C, Chandy SJ, Mathews JE, Mathews KP (2008) Acenocoumarol and phenytoin toxicity in the presence of CYP2C9 mutation. J Assoc Physicians India 56:250–252PubMedGoogle Scholar
  36. 36.
    Ramasamy K, Narayan SK, Chanolean S, Chandrasekaran A (2007) Severe phenytoin toxicity in a CYP2C9*3*3 homozygous mutant from India. Neurol India 55:408–409CrossRefPubMedGoogle Scholar
  37. 37.
    Troupin AS, Ojemann LM (1975) Paradoxical intoxication-a complication of anticonvulsant administration. Epilepsia 16:753–758CrossRefPubMedGoogle Scholar
  38. 38.
    Kutt H, Kokenge R, Winters W, Mcdowell F (1964) Diphenylhydantoin metabolism, blood levels, and toxicity. Arch Neurol 11:642–648PubMedGoogle Scholar
  39. 39.
    Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341–349CrossRefPubMedGoogle Scholar
  40. 40.
    Sanger F, Nicklen S, Coulson AR (1997) DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci USA 74:5463–5467Google Scholar
  41. 41.
    Gerson B, Bell F, Chan S (1984) Antiepileptic agents–primidone, phenobarbital, phenytoin, and carbamazepine by reversed-phase liquid chromatography. Clin Chem 30:105–108PubMedGoogle Scholar
  42. 42.
    Rosemary J, Adithan C (2007) The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr Clin Pharmacol 2:93–109CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Ramasamy Kesavan
    • 1
  • Sunil K. Narayan
    • 2
  • Chandrasekaran Adithan
    • 1
  1. 1.Department of Pharmacology, Center for Advance Research in PharmacogenomicsJawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)PondicherryIndia
  2. 2.Department of NeurologyJawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)PondicherryIndia

Personalised recommendations